Resource Capacity Planning and Modernized Time Reporting

Why It Matters

Linking user‑fee collections to actual resource needs helps the FDA keep review timelines on track, giving industry clearer cost expectations and supporting public‑health commitments.

Key Takeaways

• FDA introduced Resource Capacity Planning to forecast staffing needs
• Modernized time reporting rolled out across CBER, CDER, ORA
• Capacity Planning Adjustment aligns user fees with resource demands
• CPA first applied to FY2021 PDUFA and BsUFA fees
• GDUFA III will use CPA starting FY2024

Pulse Analysis

The FDA’s user‑fee framework—originating with PDUFA in 1992 and expanded through BsUFA and GDUFA—has become a cornerstone of drug and biologics review financing. Over the past decade, the agency has faced a surge in submission volume and scientific complexity, straining existing staffing models. To preserve timely approvals, the FDA introduced Resource Capacity Planning, a data‑driven approach that quantifies the exact mix of reviewers, scientists, and support staff required for projected workloads.

Modernized time‑reporting, first deployed in CBER in 2018 and later in CDER and ORA, captures real‑time effort across review stages. This granular data powers the Capacity Planning Adjustment (CPA) methodology, which recalibrates user‑fee rates to reflect genuine resource demands. The CPA proved its value when it adjusted FY 2021 fees for PDUFA and BsUFA, ensuring that fee revenue kept pace with staffing needs. Extending CPA to GDUFA III beginning FY 2024 signals a systematic, transparent link between fees and capacity across the entire FDA product pipeline.

Looking ahead, the five‑year implementation plan (FY 2023‑2027) aims to mature RCP tools, integrate predictive analytics, and refine fee‑setting algorithms. For pharmaceutical and biotech firms, this translates into more predictable regulatory costs and reduced risk of review delays. However, the success of the program hinges on accurate forecasting and sustained funding. As the FDA continues to refine its capacity planning, industry stakeholders will watch closely for any shifts in fee structures that could impact product launch timelines and investment decisions.